title: Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus.
abstract: To determine whether mineralocorticoid receptor (MR) activation plays a role in diabetic renal injury and whether this role differs in types 1 and 2 diabetes mellitus, we examined the effect of a MR antagonist on renal injury in rodent models of type 1 (streptozotocin-treated rat) and type 2 (db/db mouse) diabetes. We studied three groups of 8-wk-old, uninephrectomized Wistar rats for 4 wk: diabetic streptozotocin- (55 mg/kg) treated rats (n = 11), diabetic streptozotocin-treated rats receiving the MR antagonist eplerenone (n = 15), and nondiabetic rats (n = 9). In addition, we studied three groups of 8-wk-old mice for 16 wk: diabetic db/db mice (n = 10), diabetic db/db mice treated with eplerenone (n = 8), and nondiabetic, db/+ littermates (n = 11). Diabetic rats and mice developed albuminuria and histopathological evidence of renal injury, including glomerular hypertrophy, mesangial expansion, and tubulointerstitial injury as well as increased renal cortical levels of MR protein, MR mRNA, TGFbeta mRNA, and osteopontin mRNA. All of these changes were significantly reduced by treatment with eplerenone except for the elevated MR levels. The beneficial effects of eplerenone were not attributable to changes in blood pressure or glycemia. In summary, MR expression was increased in kidneys of diabetic rodents, and MR antagonists effectively reduced diabetic renal injury irrespective of the species or specific cause of the diabetes. Thus, these data suggest that MR activation is a critical factor in the early pathogenesis of renal disease in both type 1 and type 2 diabetes mellitus.
authors.affiliation: Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, Massachusetts 02115, USA.
authors.forename: Christine
authors.initials: C
authors.lastname: Guo
authors.forename: Diego
authors.initials: D
authors.lastname: Martinez-Vasquez
authors.forename: Gonzalo P
authors.initials: GP
authors.lastname: Mendez
authors.forename: Maria F
authors.initials: MF
authors.lastname: Toniolo
authors.forename: Tham M
authors.initials: TM
authors.lastname: Yao
authors.forename: Eveline M
authors.initials: EM
authors.lastname: Oestreicher
authors.forename: Taisuke
authors.initials: T
authors.lastname: Kikuchi
authors.forename: Nathalie
authors.initials: N
authors.lastname: Lapointe
authors.forename: Luminita
authors.initials: L
authors.lastname: Pojoga
authors.forename: Gordon H
authors.initials: GH
authors.lastname: Williams
authors.forename: Vincent
authors.initials: V
authors.lastname: Ricchiuti
authors.forename: Gail K
authors.initials: GK
authors.lastname: Adler
mesh_terms: D000419:Albuminuria / Q000517:prevention & control; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000150:complications* / Q000378:metabolism / Q000473:pathology; D003922:Diabetes Mellitus, Type 1 / Q000150:complications* / Q000378:metabolism / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000378:metabolism / Q000473:pathology; D003928:Diabetic Nephropathies / Q000209:etiology / Q000517:prevention & control*; D000077545:Eplerenone; D006984:Hypertrophy; D007668:Kidney / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D000451:Mineralocorticoid Receptor Antagonists; D053495:Osteopontin / Q000032:analysis / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D018161:Receptors, Mineralocorticoid / Q000235:genetics / Q000502:physiology; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D013311:Streptozocin; D013599:Systole
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D012333:RNA, Messenger; D018161:Receptors, Mineralocorticoid; D053495:Osteopontin; D013148:Spironolactone; D013311:Streptozocin; D000077545:Eplerenone